Rapivab (BioCryst Pharmaceuticals)
(https://rapivab.com) 📸 Data Snapshot: May 24, 2026
Information Density — The Lens
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Info Density
Power-words vs. Substance ratio.
29
Impact Weight: 30 / 100
97% Reputation
Information density is extremely high, with a near-zero ratio of marketing power words to specific nouns. Headings such as H4 ‘SHORTENED TIME to alleviation of symptoms’ and H5 ‘symptoms were resolved in a median of 79 hours vs. 100 hours’ provide immediate, measurable data rather than vague claims. The body text is almost entirely comprised of technical specifications, including NDC numbers like 72769-181-01 and specific vial concentrations of 10 mg/mL.
Information Density is read straight from the body copy: how much of the text carries grounded, checkable substance versus hollow filler. Below is the clean text the engine analyzed, then the industry’s known generic-claim patterns to weigh it against.
📝 The Narrative — clean text per page (the substance-vs-filler signal)
HOMEPAGE (https://rapivab.com) Flu Antiviral | Rapivab
[IMG: Rapivab] [H3] See what makes Rapivab stand out as an antiviral influenza treatment [H4] A FULL COURSE of ANTIVIRAL INFLUENZA TREATMENT IN [H4] SHORTENED TIMEto alleviation of symptoms by a median of [H5] In patients aged 6 months to 17 years, symptoms were resolved in a median of 79 hours vs. 100 hours for oseltamivir1 [H4] SHORTENED TIMEto resolution of fever by a median of [H5] In patients aged 6 months to 17 years, fever was resolved in a median of 40 hours vs. 35 hours for oseltamivir1,2 [H1] It’s easy to access and order Rapivab To order, please call 1-833-964-2956 if you are a US-based institution or health care professional. ORDER RAPIVAB References: 1. Rapivab [package insert]. Durham, NC: BioCryst Pharmaceuticals, Inc; 2021. 2. Kohno S, Kida H, Mizuguchi M, Shimada J; S-021812 Clinical Study Group. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010;54(11):4568-4574. 3. BioCryst Pharmaceuticals, Inc. Summary of clinical efficacy. Data on file. 4. Managed Markets Insights & Technology, LLC website. https://formularylookup.com/. Accessed March 16, 2021.
1191 chars
SUB-PAGE (https://rapivab.com/dosing-and-administration/) Dosing and Administration | Rapivab
[H1] Dosing & Administration [H3] One 15- to 30-minute intravenous (IV) infusion provides a full course of antiviral influenza treatment1 Use these dosing guidelines to determine the dosage of Rapivab® (peramivir injection) for your patients 6 months of age and older. The administration of Rapivab in patients with renal impairment is at the discretion of the treating physician. [H3] Preparation of Rapivab for IV infusion Use aseptic technique during the preparation of Rapivab to prevent inadvertent microbial contamination. There is no preservative or bacteriostatic agent present in the solution.1 [H4] Follow the steps below to prepare a diluted solution of Rapivab1: 1. Do not use if seal over bottle opening is broken or missing. 2. Visually inspect Rapivab for particulate matter and discoloration prior to administration. 3. Dilute an appropriate dose of RAPIVAB 10 mg/mL solution [see Dosage and Administration (2.1, 2.2)] in 0.9% or 0.45% sodium chloride, 5% dextrose, or lactated Ringer’s. The maximum infusion volume is provided in Table 3. The final concentration of diluted RAPIVAB for administration should be between 1 mg/mL and 6 mg/mL. 4. Administer the diluted solution via intravenous infusion for 15 to 30 minutes. 5. Discard any unused diluted solution of Rapivab after 24 hours. Once a diluted solution of Rapivab has been prepared, administer immediately or store under refrigerated conditions (2° to 8°C or 36° to 46°F) for up to 24 hours. If refrigerated, allow the diluted solution of Rapivab to reach room temperature, then administer immediately. Do not use if seal over bottle opening is broken or missing. Reference: 1. Rapivab [package insert]. Durham, NC: BioCryst Pharmaceuticals, Inc; 2021.
1744 chars
SUB-PAGE · THIN (https://rapivab.com/how-supplied/) How Supplied | Rapivab
[H1] How Supplied [H3] Rapivab® (peramivir injection) is supplied in convenient single-use vials Each single-use vial of Rapivab contains 200 mg per 20 mL (10 mg/mL) of peramivir in a clear glass vial (NDC #72769-181-01).1 Rapivab is supplied in cartons containing 3 single-use vials (NDC #72769-181-03).1 Reference: 1. Rapivab [package insert]. Durham, NC: BioCryst Pharmaceuticals, Inc; 2021.
412 chars
SUB-PAGE (https://rapivab.com/coding-and-billing/) Coding and Billing | Rapivab
[H1] Coding and Billing [H3] Coding and billing information for Rapivab® (peramivir injection) Use this information to facilitate coding and billing processes. Some payers will require the National Drug Code (NDC) code for Rapivab.1 [H3] Support and access for Rapivab [H4] RAPIVAB CUSTOMER SUPPORT CENTER 1-833-964-2956 and rapivab.com Current Procedural Terminology (CPT) Codes for Rapivab The following CPT codes are for treatments administered via injection to individuals. CPT Code 2 Description 96365 Intravenous (IV) infusion for therapy, prophylaxis, or diagnosis; initial, up to first hour 96366 IV med therapy−each additional hour 96374 IV med injection−first med 96375 IV med injection−second med subsequent injection 96376 IV med injection−first med subsequent injection 96360 IV hydration−first hour 96361 IV hydration−each additional hour HCPCS Code 3 Description J2547 Injection, peramivir, 1 mg Report the administration of Rapivab in addition to the treatment product code Assign the appropriate administration code based on the documentation in the medical record Medicare requires the use of an HCPCS code for the administration of Rapivab. Some payers may also require that an HCPCS code be used to report Rapivab Prior authorizations or appeals may not be completed or filed on the HCP's behalf. Revenue codes for Rapivab These codes are used to attribute hospital charges to specific cost centers. They may vary by service provided and patient status. Revenue Code 4 Description 0636 Drugs requiring detailed coding required by Medicare to obtain pass-through payment for drugs in the outpatient department 0250 Pharmacy, general 0260 Intravenous therapy, general 0450 Emergency room 0510 Clinic 0520 IV hydration–first hour ICD-10-CM codesa for Rapivab Refer to these tables when you need the ICD-10-CM codes for Rapivab. ICD-10 Code 5 Description J10.00 Influenza due to other identified influenza virus with unspecified type of pneumonia J10.01 Influenza due to other identified influenza virus with the same other identified influenza virus pneumonia J10.08 Influenza due to other identified influenza virus with other specified pneumonia J11.00 Influenza due to unidentified influenza virus with unspecified type of pneumonia J11.08 Influenza due to unidentified influenza virus with specified pneumonia J12.9 Viral pneumonia, unspecified J10.1 Influenza due to other identified influenza virus with other respiratory manifestations J11.1 Influenza due to unidentified influenza virus with other respiratory manifestations J10.2 Influenza due to other identified influenza virus with gastrointestinal manifestations J10.81 Influenza due to other identified influenza virus with encephalopathy J10.82 Influenza due to other identified influenza virus with myocarditis J10.83 Influenza due to other identified influenza virus with otitis J10.89 Influenza due to other identified influenza virus with other manifestations J11.2 Influenza due to unidentified influenza virus with gastrointestinal manifestations J11.81 Influenza due to unidentified influenza virus with encephalopathy J11.82 Influenza due to unidentified influenza virus with myocarditis J11.83 Influenza due to unidentified influenza virus with otitis media J11.89 Influenza due to unidentified influenza virus with other manifestations J09.X1 Influenza due to identified novel influenza A virus with pneumonia J09.X2 Influenza due to identified novel influenza A virus with other respiratory manifestations J09.X3 Influenza due to identified novel influenza A virus with gastrointestinal manifestations J09.X9 Influenza due to identified novel influenza A virus with other manifestations aThis may not be an all-inclusive list; see payor-specific coverage policies for covered indication. References: 1. Rapivab [package insert]. Durham, NC: BioCryst Pharmaceuticals, Inc; 2021. 2. Current Procedural Coding Expert; 2021 Chicago IL: Optum360; 2021. 3. Parman C. Hospital regulatory update. Association of Community Cancer Centers website. https://www.accc-cancer.org/oncology_issues/articles/JF16/JF16-Oncology-Coding-Reimbursement-Update.pdf. Accessed March 16, 2021. 4. CMS Manual System: Pub. 100-04 Medicare claims processing. Centers for Medicare & Medicaid Services website. https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/r167cp.pdf. Published April 30, 2004. Accessed March 16, 2021. 5. Nelson M. ICD-10 cometh. https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=5&cad=rja&uact=8&ved=0ahUKEwih4NKzjLfLAhXLTCYKHc2LAAUQFgg5MAQ&url=https%3A%2F%2Fwww.chestnet.org%2F~%2Fmedia%2Fchesnetorg%2FPublications%2FDocuments%2FCHEST%2520Physician%2FICD10InfluenzaCodes.ashx&usg=AFQjCNH5tCT-_gZ8SmRF_CZi0vB-OvUyFQ&sig2=JQocAaPEHmQ0wQsagrgHLQ&bvm=bv.116573086,d.cWw. Published April 2015. Accessed March 16, 2021.
5180 chars
🧭 Industry Context — common generic-claim patterns in Medical Devices, Pharma & Biotech to weigh the text against
Generic Claims:
advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes, pioneering medical science, the future of medicine…
Red Flags:
FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified, patient testimonials making efficacy claims, off-label promotion signals…
Semantic Drift Patterns:
homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations:
specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations, specific patent numbers and status, pharmacovigilance and adverse event reporting mechanisms…
Explore the other reputation pillars for Rapivab (BioCryst Pharmaceuticals)
Analysis Disclosure & Source Attribution
This page presents a snapshot of public data from Rapivab (BioCryst Pharmaceuticals), captured on May 24, 2026, to show how machine logic reads Information Density signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to Rapivab (BioCryst Pharmaceuticals): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://rapivab.com to view the most current version of its content and see directly what this company is about and what it offers.